Characterization of mutations and loss of heterozygosity of p53 and K-ras2 in pancreatic cancer cell lines by immobilized polymerase chain reaction by Butz, James et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Biotechnology
Open Access Methodology article
Characterization of mutations and loss of heterozygosity of p53 and 
K-ras2 in pancreatic cancer cell lines by immobilized polymerase 
chain reaction
James Butz1, Eric Wickstrom2 and Jeremy Edwards*1
Address: 1Department of Chemical Engineering, University of Delaware, Newark, DE 19716, USA and 2Department of Biochemistry and Molecular 
Pharmacology, Thomas Jefferson University, Philadelphia, PA 19107, USA
Email: James Butz - butz@che.udel.edu; Eric Wickstrom - eric@tesla.jci.tju.edu; Jeremy Edwards* - edwards@che.udel.edu
* Corresponding author    
Polonyimmobilized PCRpancreatic cancerp53K-ras2mutationsloss of heterozygosity
Abstract
Background: The identification of known mutations in a cell population is important for clinical
applications and basic cancer research. In this work an immobilized form of the polymerase chain
reaction, referred to as polony technology, was used to detect mutations as well as gene deletions,
resulting in loss of heterozygosity (LOH), in cancer cell lines. Specifically, the mutational hotspots
in p53, namely codons 175, 245, 248, 249, 273, and 282, and K-ras2, codons 12, 13 and 61, were
genotyped in the pancreatic cell line, Panc-1. In addition LOH analysis was also performed for these
same two genes in Panc-1 by quantifying the relative gene copy number of p53 and K-ras2.
Results: Using polony technology, Panc-1 was determined to possess only one copy of p53, which
possessed a mutation in codon 273, and two copies of K-ras2, one wildtype and one with a
mutation in codon 12. To further demonstrate the general approach of this method, polonies were
also used to detect K-ras2 mutations in the pancreatic cell lines, AsPc-1 and CAPAN-1.
Conclusions: In conclusion, we have developed an assay that can detect mutations in hotspots of
p53 and K-ras2 as well as diagnose LOH in these same genes.
Background
The advent of the polymerase chain reaction (PCR) played
an important role in revolutionizing research in the field
of molecular biology [1]. A recent adaptation of this tech-
nology, known as polymerase colonies, or "polonies",
holds tremendous promise as well. Polony technology is
a form of PCR in which the reaction is immobilized in a
thin polyacrylamide gel attached to a microscope slide
[2,3]. As the PCR proceeds, the PCR products diffuse radi-
ally within the gel from its immobilized template (e.g.,
genomic DNA), giving rise to a circular PCR product, or
polymerase colony. When the gel is stained with
SybrGreen I and scanned with a microarray scanner, the
polymerase colony resembles a colony on an agar plate,
hence its name. Herein, we describe the applications of
polony technology to cancer research with the goal of
screening for: 1) mutations in key tumor suppressor and
oncogenes; as well as 2) loss of heterozygosity.
One of the hallmarks of cancer includes the accumulation
of mutations in key genes, namely DNA repair genes [4],
tumor suppressor genes [5,6], and proto-oncogenes [5,6],
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accompanied by the loss of the wildtype allele, resulting
in loss of heterozygosity [LOH, see reviews by [7–9]]. Pan-
creatic cancer, which results in the death of approximately
30,000 Americans annually and is the fourth leading
cause of cancer mortalities in the United States, exhibits
this hallmark [10]. For example, in pancreatic cancer there
is a high incidence of mutations (>50%) in the tumor sup-
pressor genes p16, p53 and DPC4 and approximately
90% of cases coincide with a mutation in the oncogene K-
ras2 [see review by [11]]. Furthermore, a significant per-
centage of tumors harboring a mutated copy of DPC4 or
p53 also lose the corresponding wildtype allele, resulting
in LOH [see reviews by [11,12]].
Of particular importance to this study are the genes p53
and K-ras2 since a significant proportion of the mutations
are localized to a relatively small number of mutational
hotspots [13–16]. In this paper we introduce a screen to
detect the presence of pancreatic cancer by looking for
somatic mutations in p53 and K-ras2 using polony tech-
nology to microsequence mutational hotspots within
these two genes. In addition polonies are used to diagnose
LOH in these same genes.
Results
Previous work has shown that a significant percentage of
mutations in p53 and K-ras2 are localized to mutational
hotspots, namely codons 175, 245, 248, 249, 273, and
282 in p53 and codons 12, 13, and 61 in K-ras2 [reviewed
in [14,17,18]]. Each of these mutational hotspots was
sequenced in the genomic DNA of various pancreatic cell
lines using polony technology as follows. Initially, each
exon bearing a mutational hotspot was individually PCR
amplified in a polyacrylamide gel giving rise to one
polymerase colony, or polony, per copy of genomic p53
or K-ras2 DNA. The non-acrydited strand of the polony
was then stripped away after formamide treatment and
electrophoresis. A sequencing primer was hybridized to
the single-stranded copy of the PCR-amplified p53/K-ras2
fragment and a single base extension with either a Cy-3 or
Cy-5 labeled dNTP was performed prior to scanning on a
microarray scanner. The process of formamide denatura-
tion, hybridization, and extension was repeated 3 addi-
tional times in order to perform an extension with each of
the four dNTPs and completely sequence each position.
When all the mutational hotspots were sequenced in the
Panc-1 cell line (results of sequencing in Table 3), it was
determined that K-ras2 was heterozygous (i.e. one mutant
and one wild type allele) at the second position of codon
12 (Figure 1) and p53 harbored a mutation at the second
position of codon 273 (Figure 2). In addition to the cell
line Panc-1, K-ras2 mutations in the second position of
codon 12 were also shown to be present in the cell lines
AsPC-1 (G → A; data not shown) and CAPAN-1 (G → T;
data not shown). These results are in agreement with pre-
viously published data concerning the genotype of these
cell lines [19–21].
One hallmark of cancer that can be readily observed using
polonies is loss of heterozygosity (LOH). Polony technol-
ogy provides this capability due to its "digital" nature,
where one DNA molecule gives rise to one polony. As a
result, polonies can be used to detect changes in gene copy
number that arise due to either deletions or multiplica-
tions. For example, previous studies have shown that
Panc-1 has two copies of K-ras2, but only one copy of p53,
due to LOH [20]. When equivalent quantities of Panc-1
genomic DNA were polony amplified, there were approx-
imately twice as many K-ras2 polonies as there were p53
polonies (Figure 3). These results, taken in conjunction
with the in situ genotyping shown previously in Figures 2
and 3, clearly demonstrate the ability of polonies to detect
LOH. It should be noted that polony amplification of
genomic DNA from strains with equal p53 and K-ras2
copy numbers, such as CAPAN-1, yielded equivalent
numbers of p53 and K-RAS2 polonies (data not shown).
This eliminates the role of primer bias contributing to the
distinct number of p53 and K-ras2 polonies amplified in
Panc-1 genomic DNA.
The second position of codon 12 in K-ras2 of Panc-1  genomic DNA is heterozygous with roughly half the alleles  being wildtype {G} and with the other half being mutant {A} Figure 1
The second position of codon 12 in K-ras2 of Panc-1 
genomic DNA is heterozygous with roughly half the alleles 
being wildtype {G} and with the other half being mutant {A}. 
(A) All K-ras2 exon1 polonies are shown following Sybr 
Green I staining. (B) After the polonies were made single-
stranded, a sequencing primer was hybridized to the polony 
and the position was shown to be heterozygous by perform-
ing independent single base extensions with Cy-5 labeled: 
dATP (blue) and dGTP (red). Extensions with Cy-5 labeled 
dCTP and dUTP did not yield any significant signal (data not 
shown). Colors are artificial in both images.BMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/11
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Discussion
We have shown that polony technology is an improved
method to study, and potentially diagnosis, cancer [22].
Specifically, polony technology was successfully applied
to both detect intragenic mutations in well-defined muta-
tional hotspots in key cancer genes as well as determine if
loss of heterozygosity of these same genes had occurred.
For example, Panc-1 was determined to possess only one
copy of p53, which possessed an intragenic mutation in
codon 273, and two copies of K-ras2, one wildtype and
one with an intragenic mutation in codon 12. These
results are consistent with findings from previous work
[20,21].
The approach described herein was applied to a clonal cell
line. However, this approach could be used to detect rare
somatic mutations and to diagnosis cancer with genomic
DNA collected from patient samples or biopsies [23–27]
in a manner similar to Digital PCR developed by Vogel-
stein and Kinzler [22]. In the case of analyzing pancreatic
juice for p53 and K-ras2 mutations, it seems likely that
only a small percentage of DNA harbors mutant DNA.
However, polonies seem well suited for this type of anal-
ysis since several hundred to several million [2] polonies
for a particular gene can be analyzed on a single slide,
thereby increasing the likelihood of detecting a rare event
[22]. Additionally, the frequency of mutations can be
readily determined using this approach due to the "dig-
ital" nature of polonies.
Finally, it should be noted that this approach is not with-
out limitations. For example, sequencing each mutational
hotspot is laborious and detecting mutations outside the
hotspots is not feasible. Adherence to mutational
hotspots was directly responsible for the inability to detect
the p53 mutations in the CAPAN and AsPc-1 cell lines
[19,21]. The best approach for detecting mutations out-
side the hotspots will involve direct sequencing of the pol-
ony PCR products [2,13,14].
Conclusions
We have shown that polony technology is an improved
method to study, and potentially diagnosis, cancer [22].
Specifically, polony technology was successfully applied
to both detect intragenic mutations in well-defined muta-
tional hotspots in key cancer genes as well as determine if
loss of heterozygosity of these same genes had occurred.
These results are consistent with findings from previous
work [20,21].
The second position of codon 273 in p53 of Panc-1 is  mutated, possessing an "A" instead of a "G" Figure 2
The second position of codon 273 in p53 of Panc-1 is 
mutated, possessing an "A" instead of a "G". (A) All p53 exon 
8 polonies are shown following Sybr Green I staining. (B) The 
position was shown to harbor a G → A mutation by per-
forming independent single base extensions with Cy-5 
labeled: dATP (blue) and dGTP (red). Extensions with Cy-5 
labeled dCTP and dUTP did not yield any significant signal 
(data not shown). Colors are artificial in both images.
Loss of heterozygosity analysis of K-ras2 and p53 in Panc-1 Figure 3
Loss of heterozygosity analysis of K-ras2 and p53 in Panc-1. 
There are approximately twice as many (A) K-ras2 polonies 
than (B) p53 polonies following the polony amplification of 
equal amounts of genomic DNA, likely indicating that one of 
two p53 alleles was lost. These results, coupled with the 
sequencing of mutational hotspots in these same genes, dem-
onstrate that p53 experienced LOH.BMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/11
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Methods
Preparation of Pancreatic Cell Line Genomic DNA
The pancreatic cell lines AsPc-1, CAPAN-1 and Panc-1
were purchased from the American Type Culture Collec-
tion (Manassas, VA) and were grown according to the
manufacturer's instructions [28–30]. Genomic DNA was
harvested from these cells using a Qiagen (Alameda, CA)
Blood and Cell Culture DNA Midi Kit.
Table 1: Primers used to polony amplify p53 and K-ras 2 exons bearing mutational hotspots from pancreatic cancer cell line genomic 
DNA.
Primer Name Sequence
p53 exon5 forward tgccctgactttcaactctgtctccttcctc
p53 exon5 reverse ccagacctaagagcaatcagtgaggaatcagaggc
p53 exon7 forward gttatctcctaggttggctctgactgtacca
p53 exon7 reverse gtggatgggtagtagtatggaagaaatcggt
p53 exon8 forward ggtaggacctgatttccttactgcctcttgc
p53 exon8 reverse gataaaagtgaatctgaggcataactgcacc
kras exon1 forward tggtggagtatttgatagtgtattaaccttatgtg
kras exon1 reverse agagaaacctttatctgatatcaaagaatggtcctg
kras exon2 forward tgaagtaaaaggtgcactgtaataatccagac
kras exon2 reverse taatgtcagcttattatattcaatttaaacccacc
Table 2: Primers used to sequence codons in p53 and K-ras2 that experience a high incidence of mutation during carcinogenesis. The 
designations "for" and "rev" indicate whether the anti-sense or sense strand was sequenced, respectively.
Primer Name Sequence
p53 c175 pos1 for gcacatgacggaggttgtgagg
p53 c175 pos2 for gcacatgacggaggttgtgaggc
p53 c175 pos3 for gcacatgacggaggttgtgaggcg
p53 c175 pos3 rev cagcgctcatggtggggggca
p53 c175 pos2 rev cagcgctcatggtggggggcag
p53 c245 pos1 for gtaacagttcctgcatgggc
p53 c245 pos2 for gtaacagttcctgcatgggcg
p53 c245 pos3 for gtaacagttcctgcatgggcgg
p53 c248 pos1 for cctgcatgggcggcatgaac
p53 c248 pos2 for cctgcatgggcggcatgaacc
p53 c248 pos3 for cctgcatgggcggcatgaaccg
p53 c249 pos3 rev gtgatgatggtgaggatggg
p53 c249 pos2 rev gtgatgatggtgaggatgggc
p53 c249 pos1 rev gtgatgatggtgaggatgggcc
p53 c273 pos1 for gacggaacagctttgaggtg
p53 c273 pos2 for gacggaacagctttgaggtgc
p53 c273 pos3 for gacggaacagctttgaggtgcg
p53 c282 pos1 for gtgcctgtcctgggagagac
p53 c282 pos2 for gtgcctgtcctgggagagacc
p53 c282 pos3 for gtgcctgtcctgggagagaccg
kras c12 pos1 for aacttgtggtagttggagct
kras c12 pos2 for aacttgtggtagttggagctg
kras c12 pos3 for aacttgtggtagttggagctgg
kras c13 pos3 rev gtcaaggcactcttgcctac
kras c13 pos2 rev gtcaaggcactcttgcctacg
kras c13 pos1 rev gtcaaggcactcttgcctacgc
kras c61 pos1 for atattctcgacacagcaggt
kras c61 pos2 for atattctcgacacagcaggtc
kras c61 pos3 for atattctcgacacagcaggtcaBMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/11
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Polony gels
Polony gels for genotyping mutational hotspots were cast
on Teflon-printed microscope slides as described by Mitra
et al [3]. The Teflon-printed, 24.4 × 16.7 mm oval slides
(Grace Bio-Labs, Bend, OR) were treated with Bind Silane
(Amersham, Piscataway, NJ) in accordance with the man-
ufacture's instructions. The slides were stored in a desicca-
tor. To cast the polyacrylamide gels used for the
immobilized PCR reaction, a master mix was first made
for 12 polony gels (131.0 µL of filter-sterilized doubly
deionized water, 25.5 µL of 10X JumpStart Taq Polymer-
ase Reaction Buffer (Sigma, St. Louis, MO), 2.55 µL of
dNTP (20 mM each), 1.5 µL of 30% BSA (Sigma), 2.55 µL
10% Tween 20, and 56.16 µL of degassed, filter-sterilized
acrylamide). For each position within a mutational
hotspot to be genotyped, 20 µL of master mix was com-
bined with 1 µL of genomic DNA as well as 0.23 µL of
each the forward and reverse primers (50 µM each; see
Table 1) designed to polony amplify the portion of the
exon bearing the mutational hotspot(s). Depending on
whether the sense or anti-sense strand was to be
sequenced, either the forward or reverse primer was mod-
ified with a 5' acrydite to covalently attach the PCR prod-
uct to the acrylamide matrix (see below). Immediately
prior to casting the polony gel, 1.38 µL of JumpStart Taq
Polymerase (Sigma), 0.34 µL of 5% APS, and 0.34 µL of
TEMED was added to the master mix/primer/DNA solu-
tion. The gel was polymerized for 10 min, a hybrid well
cover (Grace Bio-labs) was placed on top of the gel and
light mineral was pipeted into the hybrid well chamber.
The slide was placed in a placed in an in situ PCR tower
(MJ Research, MA) and thermalcycled (94 C for 2 min; 39
cycles of 94 C for 15 s, (Tm-3) C for 30 s and 72 C for 30
s; final extension at 72 C for 2 min). (Note: Tm is the melt-
ing temperature of the PCR primer with the lower melting
temperature in a given primer pairing.)
Upon completion of the PCR reaction, the slide was
immersed in clean hexane to remove oil prior to staining
in 2X Sybr Green (Molecular Probes, Eugene, OR) for 15
minutes. The slides was then washed in TBE and scanned
with a ScanArray 5000 microarray scanner (Perkin Elmer,
Wellesley, MA) with the FITC laser and filter set.
Denaturation and electrophoresis of polony gels
Prior to genotyping, the double stranded polonies were
made single stranded by stripping away the non-acrydited
strand in a two-step procedure [3]. The polony DNA was
denatured by incubation in a formamide buffer (1x SSC,
70% formamide, 25% doubly deionized-water) at 70 C
for 15 min. Immediately following denaturation, the gels
were subjected to electrophoresis (42 % urea in 0.5x TBE)
to remove the non-acrydited strand.
Hybridization and single base extension
After electrophoresis, the polony slides were washed 4× in
wash 1E (0.1 M Tris-HCl, pH 7.5, 20 mM EDTA, 0.5 M
KCl) to prepare for hybridization of the sequencing
primer. 200 µL of annealing buffer (6x SSPE, 0.01% Tri-
ton X-100) containing 0.5 µM primer (Table 2) was then
pipeted onto the gel and covered with a hybrid well cham-
ber. The slide was then incubated for 2 min at 94 C fol-
lowed by 20 min at (Tm-3) C to facilitate hybridization.
Genotyping of mutational hotspots was finally accom-
plished by performing single base extensions of the
hybridized sequencing primer with fluorescently labeled
deoxynucleotides. Following hybridization, the gels were
washed 2× in Wash1E and then equilibrated in Klenow
extension buffer (50 mM Tris-HCl, pH 7.5, 5 mM MgCl2,
0.01% Triton X-100) for 1 minute. For each sample, 50 µL
solution containing approximately 5 units of Klenow
large fragment (New England Biolabs, Beverly, MA), 3 µg
of single stranded binding protein (US Biochemicals,
Cleveland, OH), and 0.5 µM Cy3- or Cy5-labeled dATP,
dCTP, dGTP or dUTP (Perkin Elmer) was pipeted onto the
gel. The single base extension was allowed to proceed for
2 min. The gels were then washed in Wash1E to reduce
background fluorescence and scanned on the
ScanArray5000 with the appropriate lasers and filters. The
process of formamide denaturation, hybridization, exten-
sion, and scanning was repeated 3 additional times for
Table 3: Results from sequencing p53 and K-ras 2 mutational hotspots in Panc-1 genomic DNA.
K-ras
codon strand sequenced wt Panc-1
12 anti-sense GGT G G/A T
13 sense CCG CCG
61 anti-sense CAA CAA
p53
codon strand sequenced wt Panc-1
175 anti-sense CGC CGC
245 anti-sense GGC GGC
248 anti-sense CGG CGG
249 sense TCC TCC
273 anti-sense CGT CAT
282 anti-sense CGG CGGPublish with BioMed Central    and   every 
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each primer in order to do a single base extension with
each of the four labeled nucleotides.
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